IBA Issues Transparency Notification Due to Axxion S.A. Holdings Change

IBA, the world leader in proton therapy solutions, has issued a transparency notification to the market, as required by Article 14, paragraph 1 of the Transparency Law of May 2, 2007, on disclosure of major holdings. The notification follows an acquisition or disposal of securities or voting rights by Axxion S.A., which resulted in the company crossing below the 1% threshold on August 27, 2026.

According to the notification, Axxion S.A. reported a change in its holdings, indicating that it had fallen below the 1% threshold following an unspecified transaction. The notification provides details of the company's holdings, including the full chain of controlled undertakings through which the holding is effectively held, which, in this case, is Axxion S.A. itself, as it is not controlled by any other entity.

IBA, headquartered in Louvain-la-Neuve, Belgium, is a certified B Corporation and the global leader in particle accelerator technology. The company is renowned for its proton therapy solutions, a form of advanced radiation therapy used in cancer treatment, as well as for its contributions to industrial sterilization, radiopharmaceuticals, and dosimetry. With a global workforce of approximately 2,300 employees, IBA remains committed to advancing medical technology and improving patient care.

The notification is part of IBA’s ongoing efforts to maintain transparency and comply with regulatory requirements. The company's listing on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) ensures that its activities and financial health are continuously monitored by the market.